Drug intelligence / Profile preview

NBP606

Development stage: Phase 3
Lead developer: SK bioscience
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

NBP606 is a 13-valent pneumococcal vaccine conjugate developed by SK Bioscience (a subsidiary of SK Chemicals) for the prevention of pneumococcal infections. The vaccine contains purified capsular polysaccharides from 13 serotypes of Streptococcus pneumoniae conjugated to a carrier protein. It works as an immunostimulant, triggering the immune system to produce antibodies against pneumococcal bacteria. The development of NBP606 was discontinued in September 2021 after reaching Phase 3 clinical trials in South Korea.

Brand names: SKYPneumo
Other names: 13-valent pneumococcal vaccine conjugate13vPnC

Targets

CPS (Streptococcus pneumoniae capsular polysaccharide)

Beyond the preview

Go deeper on NBP606.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NBP606.

Explore the full profile